Clinical Trials Logo

Arthritis clinical trials

View clinical trials related to Arthritis.

Filter by:

NCT ID: NCT06217172 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

RHEUPP - A Rheumatological Follow-up Management App

RHEUPP
Start date: January 2024
Phase: N/A
Study type: Interventional

The purpose of this Non-inferiority Randomized Clinical Trial is to evaluate the effectiveness of RHEUPP App during telehealth follow-up in a population of Rheumatoid Arthritis patients from a Tertiary Rheumatology Service in South Brazil. The main question[s] it aims to answer are: • Using RHEUPP App in telemedicine is not inferior to usual care in terms of means obtained by CDAI. Participants will be stratified by CDAI and then randomized 1:1 for intervention or control group. They will be evaluated at study starting, in 3 and 6 months, an extended evaluation after 12 months of recruitment is predicted. Researchers will compare intervention and control group to detect differences between usual care and Telehealth follow-up and determine if the last is not less effective in our study population of rheumatic patients.

NCT ID: NCT06215638 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

bortezomib4ra
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The goal of this prospective single-arm open-label trial is to learn about efficacy and safety of Bortezomib in treating patients with difficult-to-treat rheumatoid arthritis. The main questions it aims to answer are: - Is Bortezomib an effective treatment option for patients with difficult-to-treat rheumatoid arthritis? - Is Bortezomib safe enough in treating patients with difficult-to-treat rheumatoid arthritis? Participants will: - Receive Bortezomib 2 mg per week subcutaneously for twelve weeks in total. - Follow-up at weeks 4, 12, and 24, while biosamples will be collected.

NCT ID: NCT06213259 Recruiting - Clinical trials for Rheumatoid Arthritis

A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)

Start date: January 6, 2024
Phase: Phase 1
Study type: Interventional

This phase 1 study will consist of two parts: Phase 1a is a single-dose study, and will evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary pharmacodynamics (PD) in healthy participants. Phase 1b is a multiple doses study, and will evaluate the safety, tolerability, PK and preliminary PD in participants with rheumatoid arthritis (RA).

NCT ID: NCT06209879 Recruiting - Dry Eye Syndromes Clinical Trials

Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis

Start date: February 5, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy of hydroxypropyl guar-and hyaluronic acid containing lubricant eye drops in rheumatoid arthritis patients . The main question it aims to answer is: • whether adding hydroxypropyl guar-and hyaluronic acid containing lubricant eye drops to steroid-based dry eye therapy improves dry eye symptoms in rheumatoid arthritis patients after 1 month. Participants with rheumatoid arthritis will be treat with SYSTANE™ Hydration Lubricant Eye Drops (1-2 drops 4 times a day) and 0.1% Fluorometholone (1-2 drops 3 times a day) in both eyes for 12 weeks

NCT ID: NCT06201416 Recruiting - Clinical trials for Rheumatoid Arthritis

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

Regulate-RA
Start date: March 6, 2024
Phase: Phase 1
Study type: Interventional

This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown.

NCT ID: NCT06197074 Recruiting - Clinical trials for Rheumatoid Arthritis

Effect of Quadriceps Muscle on Physical Outcome Measures in Women With Rheumatoid Arthritis

Start date: December 25, 2023
Phase:
Study type: Observational

Studies have reported that individuals with Rheumatoid Arthritis have a smaller muscle cross-sectional area, pennation angle and muscle thickness than healthy controls. Sarcopenia may decrease physical performance and quality of life in individuals with RA. Therefore, morphologic changes in the quadriceps femoris muscle due to sarcopenia may help us to gain insight into physical function and quality of life. This study aims to evaluate the predictive capacity of morphologic characteristics of the quadriceps femoris muscle for disease activity, physical performance, and quality of life in women with Rheumatoid Arthritis.

NCT ID: NCT06196359 Completed - Rehabilitation Clinical Trials

Assessing Function and Pain After Total Knee Arthroplasty With Combined Femoral and Popliteal Nerve Block

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The goal of this interventional study is to examine whether a pain management technique of combined femoral and popliteal nerve block is effective in total knee arthroplasty patients. The main questions it aims to answer are: Are there differences in postoperative outcomes? Does the nerve block, age, preoperative quadriceps muscle strength and Oxford Knee Score of the patient predict early functional ability? Participants underwent total knee arthroplasty and assessments. Researchers compared pain management techniques to assess effects on postoperative outcomes and identified the importance of preoperative variables a predictors of early functional ability. Further research is required to refine postoperative pain management strategies.

NCT ID: NCT06193681 Not yet recruiting - Clinical trials for Juvenile Idiopathic Arthritis

Efficiency of Supervised Exercise Program Versus Mobile-Based Exercise Program in Juvenile Idiopathic Arthritis

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Juvenile Idiopathic Arthritis (JIA) is a heterogeneous, idiopathic, chronic inflammatory, rheumatic disease that is most common in childhood and is thought to involve immunological mechanisms in its etiopathogenesis. Exercise and physical activity (PA) approaches have an important place in the treatment of childhood rheumatic diseases. These approaches alleviate both the symptoms of children and adolescents' chronic diseases and complications secondary to pharmacological treatments, and prevent the occurrence of new chronic diseases. However, it is difficult to draw conclusions regarding the effects of exercise types on patients with JIA, as there are few comparative studies in the literature investigating the superior effects of exercise programs on disease-specific problems. Physical, individual, social and psychological factors that create barriers to PA and exercise participation in children and adolescents with rheumatic disease significantly affect PA and exercise adherence. In this regard, online applications stand out as an important strategy for encouraging behavioral change, providing motivational and social support, and allowing feedback and interaction with health professionals using information and communication technologies. It is emphasized that digital health applications should be designed more comprehensively and personalized to increase participation in PA promotion and regular exercise programs and be compared with control group exercise programs in order to increase their usability in this disease population and examine their effectiveness. This study will be planned as a randomized controlled study. Adolescent JIA patients between the ages of 12-18 will be included in the study and will be divided into 2 groups. The first group will receive a personalized exercise program under the supervision of a physiotherapist, 3 sessions per week (2 session face to face, 1 session online) for 12 weeks. A personalized mobile application-based exercise program will be applied to the second group for the same week and frequency. This study can contribute to the literature by investigating effective methods in improving physical fitness, physical activity, walking and balance functions in patients with JIA. Adolescents in both groups will be given smart watches to promote PA and monitor health parameters. The evaluation periods for both groups are stated below; T0: Start T1: Before the exercise program (after 3 months of PA monitoring with a smart watch) T2: It will be carried out after the exercise program (12 weeks later). The effectiveness of the exercise program to be applied on the evaluation parameters will be demonstrated by comparing the two groups after the exercise program.

NCT ID: NCT06191042 Recruiting - Psoriatic Arthritis Clinical Trials

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

Start date: January 22, 2024
Phase: Phase 1
Study type: Interventional

The main objective of this study is to investigate the safety and tolerability of si-544. Other objectives are to study the metabolism of si-544 in the body and to assess the effects of si-544 on cells of the body's immune system (immune cells) that have been chronically activated by the disease. Likewise, the effect of si-544 on inflammatory responses in the body triggered by the disease and other disease symptoms will be investigated.

NCT ID: NCT06189495 Not yet recruiting - Clinical trials for Systemic Sclerosis Associated Interstitial Lung Disease

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

Start date: December 30, 2023
Phase: Phase 2
Study type: Interventional

This study was conducted in a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of Genakumab injection in the treatment of CTD-ILD including Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) and Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)